SIERRA ONCOLOGY
"SIERRA ONCOLOGY" is a word mark owned by GlaxoSmithKline LLC, filed at the EUIPO on July 3, 2017. It is registered and covers classes 5, 38, 42 and 44.
- Status
- Registered
- Since January 4, 2018
- Filed
- July 3, 2017
- Registered
- December 27, 2017
- Expires
- July 3, 2027
- Application no.
- 016949109
- Registration no.
- 016949109
- Office
- EUIPO
- European Union Intellectual Property Office
- Mark type
- Word mark
- 4 classes
Who owns SIERRA ONCOLOGY
The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.
Owner
GlaxoSmithKline LLC
Representative
Zivko Mijatovic & Partners
Zivko Mijatovic & Partners
What the mark covers
The products and services SIERRA ONCOLOGY is filed for, grouped by Nice class.
Biological and chemical preparations for the treatment of cancer; Pharmaceutical products, preparations, and compounds for the prevention and treatment of cancer and tumors; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders but specifically excluding biological eye tissue, corneas, and other ocular or eye-related human tissue intended for subsequent tissue and organ implantation; Pharmaceutical preparations for use in dermatology, oncology, hematology and for gastroenterological disorders but specifically excluding biological eye tissue, corneas, and other ocular or eye-related human tissue intended for subsequent tissue and organ implantation
Providing links to the websites of others featuring information about the diagnosis and treatment of cancer; providing links to the websites of others
Development of pharmaceutical preparations and medicines; drug discovery services; pharmaceutical drug development services; research relating to medicines; medical research; pharmaceutical research and development services; medical research services in the field of cancer; research and development of biological and chemical preparations for the treatment of cancer; research and development of pharmaceutical products, preparations and compounds for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; research and development of pharmaceutical preparations for use in dermatology, oncology, hematology, and for gastroenterological disorders; information, consultancy and advisory services relating to all of the aforesaid
Medical services; medical services for the treatment of cancer; medical analysis services; medical analysis services for the diagnosis of cancer; providing cancer screening services; providing a website via a global computer network featuring information in the fields of health, cancer, cancer treatment, recovery and survival; medical evaluation services; medical evaluation and diagnosis of cancer; RNA or DNA analysis for cancer diagnosis and prognosis; medical services for the diagnosis of conditions of the human body; providing a website via a global computer network featuring information in the fields of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; providing a website via a global computer network featuring information in the fields of dermatology, oncology, hematology, and for gastroenterological disorders; information, consultancy and advisory services relating to all of the aforesaid
What has happened so far
Steps recorded by the EUIPO, newest first.
- Bulletin 2023/134 Section C.1.1
- Bulletin 2023/022 Section C.1.3
- Bulletin 2022/199 Section C.1.3
- Bulletin 2022/196 Section C.2.2
- Bulletin 2022/109 Section C.1.3
- Bulletin 2021/133 Section C.2.2
- Bulletin 2021/002 Section C.2.2
- Bulletin 2019/096 Section C.2.1
- Bulletin 2018/185 Section C.3.2
- Bulletin 2018/002 Section B.1
1 earlier step on the official record.
About SIERRA ONCOLOGY
Who owns the trademark "SIERRA ONCOLOGY"?
The EUIPO trademark "SIERRA ONCOLOGY" (application 016949109) is owned by GlaxoSmithKline LLC.
What is the status of "SIERRA ONCOLOGY"?
Its status at the EUIPO is: registered.
When was "SIERRA ONCOLOGY" registered?
It was registered on December 27, 2017 and is due to expire on July 3, 2027.
Get this data via the API
Everything on this page comes from the Signa API. Pull SIERRA ONCOLOGY and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019d44c2-96bc-725b-83fc-ee7f7ad79fac
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019d44c2-96bc-725b-83fc-ee7f7ad79fac",
"object": "trademark",
"mark_text": "SIERRA ONCOLOGY",
"status": {
"primary": "active",
"stage": "registered"
},
"office_code": "EM",
"application_number": "016949109",
"filing_date": "2017-07-03",
"nice_classes": [
5,
38,
42,
44
],
"owners": [
{
"name": "GlaxoSmithKline LLC",
"entity_id": "ent_019ebbad-4be6-7544-bafb-06b4c2a2ecb2"
}
]
}